Program
ivarmacitinib
Also written as “SHR0302”, “SHR0302 Tablets” and “SHR0302 Base Gel”.
Its studies are mostly in Arthritis, Rheumatoid · Vitiligo · Alopecia Areata · Colitis, Ulcerative · Dermatitis, Atopic, led by Jiangsu HengRui Medicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 254 open or running | phase 3since Apr 2, 2020 | Apr 7, 2015 | Mar 2027phase 2 · NCT07251595 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 10 studies since Apr 7, 2015.
- Jul 15, 2020Phase 3 study in Spondylitis, AnkylosingNCT04481139 · 504 enrolled · China
- Jan 11, 2021Phase 1 study in Healthy SubjectsNCT04712838 · 24 enrolled · China
- Feb 24, 2021Phase 3 study in VitiligoNCT04774809 · 75 enrolled · China
- May 1, 2021Phase 3 study in Dermatitis, AtopicNCT04875169 · 336 enrolled · Canada, China
- Sep 8, 2021Phase 1 study in Arthritis, RheumatoidNCT05047341 · 6 enrolled · China
- Dec 10, 2021Phase 3 study in Colitis, UlcerativeNCT05181137 · 368 planned · United States, China, Georgia and more
- Apr 6, 2022Phase 3 study in Non-Radiographic Axial SpondyloarthritisNCT05324631 · 300 enrolled · China
- May 23, 20222 phase 1 studies in Arthritis, RheumatoidNCT05392127, NCT05404724
- Jul 20, 2022Phase 3 study in Alopecia AreataNCT05470413 · 330 enrolled · China
- May 4, 2023Phase 1 study in Graft vs Host DiseaseNCT05856058 · 16 enrolled · China
- Jan 1, 2024Phase 1 study in Autoimmune DiseasesNCT06202612 · 16 enrolled · China
- Jan 20, 2025Phase 2 study in VitiligoNCT06790862 · 155 enrolled · China
- Jul 27, 2025Phase 1 study in Preoperative Sedation of AdultsNCT07098117 · 32 enrolled · China
- Nov 19, 2025Phase 2 study in Non-segmental VitiligoNCT07251595 · 176 planned · China
Ahead
- Mar 2027Primary completion: phase 2 study in Non-segmental VitiligoNCT07251595
TargetBeta
“The sulfate salt form of ivarmacitinib, an orally available inhibitor of Janus-associated kinase 1 (JAK1), ”NCIt, by rule
Other programs on JAK1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ruxolitinibrule | Incyte | phase 4 | 95 |
| tofacitinibrule | Pfizer | phase 4 | 94 |
| upadacitinibrule | AbbVie | phase 4 | 64 |
| baricitinibrule | Eli Lilly | phase 4 | 59 |
| filgotinib maleaterule | Eisai | phase 4 | 2 |
| filgotinibrule | Lakefront Biotherapeutics NV | phase 3 | 46 |
| jaktinibrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 31 |
| abrocitinibrule | Pfizer | phase 3 | 30 |
| brepocitinibrule | Pfizer | phase 3 | 25 |
| delgocitinibrule | LEO Pharma | phase 3 | 21 |
| momelotinibrule | GlaxoSmithKline | phase 3 | 17 |
| golidocitinibrule | Dizal Pharmaceuticals | phase 3 | 10 |
Studies
All 25 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07251595Non-segmental Vitiligo · China | 2 | Recruiting | Mar 2027 | 176 |
| NCT07098117Preoperative Sedation of Adults · China | 1 | Completed | Jul 31, 2024 | 32 |
| NCT06790862Vitiligo · China | 2 | Active, not recruiting | Mar 3, 2026 | 155 |
| NCT06202612Autoimmune Diseases · China | 1 | Completed | Feb 21, 2024 | 16 |
| NCT05856058Graft vs Host Disease · China | 1 | Completed | Jul 3, 2023 | 16 |
| NCT05470413Alopecia Areata · China | 3 | Active, not recruiting | Oct 31, 2023 | 330 |
| NCT05404724Arthritis, Rheumatoid · China | 1 | Completed | Jul 11, 2022 | 14 |
| NCT05392127Arthritis, Rheumatoid · China | 1 | Completed | Aug 18, 2022 | 24 |
| NCT05324631Non-Radiographic Axial Spondyloarthritis · China | 3 | UNKNOWN | Aug 30, 2024 | 300 |
| NCT05181137Colitis, Ulcerative · United States, China, Georgia and more | 3 | Recruiting | Oct 31, 2024 | 368 |
| NCT05047341Arthritis, Rheumatoid · China | 1 | Completed | Sep 19, 2021 | 6 |
| NCT04875169Dermatitis, Atopic · Canada, China | 3 | Completed | Aug 12, 2022 | 336 |
| NCT04774809Vitiligo · China | 3 | Terminated | Mar 21, 2022 | 75 |
| NCT04712838Healthy Subjects · China | 1 | Completed | Apr 13, 2021 | 24 |
| NCT04481139Spondylitis, Ankylosing · China | 3 | Completed | Nov 15, 2022 | 504 |
| NCT04333771Arthritis, Rheumatoid · China | 3 | Completed | Jan 30, 2023 | 566 |
| NCT04293029Hepatic Impairment · China | 1 | Completed | Dec 27, 2020 | 24 |
| NCT04346316Alopecia Areata · United States, Australia, China | 2 | Completed | Jun 10, 2021 | 94 |
| NCT04162899Dermatitis, Atopic · China | 2 | Completed | Aug 21, 2020 | 105 |
| NCT03677648Crohn Disease · United States, China, Poland and more | 2 | Completed | Sep 16, 2021 | 112 |
| NCT03675477Colitis, Ulcerative · United States, China, Poland and more | 2 | Completed | Nov 30, 2020 | 164 |
| NCT03254966Arthritis, Rheumatoid · China | 2 | Completed | Apr 16, 2019 | 194 |
| NCT02892370Arthritis, Rheumatoid · China | 1 | UNKNOWN | Sep 2016 | 14 |
| NCT02665910Arthritis, Rheumatoid · China | 1 | UNKNOWN | Dec 2016 | 48 |
| NCT02423538Arthritis, Rheumatoid · China | 1 | UNKNOWN | Jul 2016 | 64 |
How it is read
Names in the registry
- “SHR0302”, 21 entries
- “SHR0302 Tablets”, 2 entries
- “SHR0302 Base Gel”, 2 entries
- “SHR0302Base gel”, 1 entry
- “SHR0302 quick release tablets”, 1 entry
Codes read as this program: SHR0302.
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 8 studies
- Vitiligo, 3 studies
- Alopecia Areata, 2 studies
- Colitis, Ulcerative, 2 studies
- Dermatitis, Atopic, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.